PhotoPharmics expands its board as its fully enrolled Phase 3 Parkinson’s trial nears top-line results. New directors deepen clinical, regulatory, and capital-markets expertise as the company prepares for FDA submission and strategic partnerships.
by Mark Tullis
Ecosystem
-
Dec 03, 2025
Utah Leads a Pro-Human Approach to Artificial Intelligence at the 2025 AI Summit
by Mark Tullis